探索银屑病的疾病共病及时间性疾病进展:一项观察性、回顾性、多数据库队列研究
该观察性队列研究利用丹麦国家患者登记库(DNPR)1999至2013年数据,分析17 683例银屑病患者诊断前后5年的共病轨迹,并与10 000个对照组的无银屑病人群比较。共121种共病达到最低标准,38种与银屑病关联的相对风险(RR)>1(P<0.001),其中19种方向为银屑病至共病,4种为共病至银屑病,4条三步共病轨迹具有显著方向性。作者认为共病轨迹可辅助临床风险分析和治疗规划。
要点
- 17 683例银屑病患者中121种共病在诊断前后5年内发生率≥0.8%。
- 38种共病与银屑病关联的RR>1(P<0.001),19种方向为银屑病至共病。
- 4条三步共病轨迹中4条具有RR>1(P<0.001)及显著方向性。
核心结论
- 共病轨迹可能支持临床医生对银屑病患者进行疾病风险分析,并帮助规划最佳治疗以预防未来高风险共病。
研究设计与样本
- 观察性、回顾性、多数据库队列研究,利用丹麦国家患者登记库(DNPR)1999至2013年数据,纳入17 683例银屑病患者并与10 000个无银屑病对照组比较。
主要发现
- 121种共病达到银屑病队列中≥0.8%患者在诊断前后5年内被诊断的最低标准。
- 38种共病与银屑病关联的RR>1(P<0.001),其中19种方向为银屑病至共病(包括银屑病至甲状腺功能减退),4种方向为共病至银屑病(包括克罗恩病至银屑病)。
- 5条含三个连续诊断的共病轨迹中4条达到RR>1(P<0.001)且方向为银屑病至第一种共病至第二种共病(包括银屑病至高血压至心房颤动和扑动)。
关键数值与推荐
- 共病在银屑病队列中发生率≥0.8%才纳入分析;若某共病在超过九个对照组中发生率高于银屑病队列,则不分析。
- 银屑病与共病诊断关联强度用相对风险(RR)衡量,RR>1且P<0.001的配对定义为Diagnosed Pair。
- Diagnosed Pair用二项检验判断方向性,Bonferroni校正P值<0.025认为方向显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Comorbidities associated with psoriasis are well documented. However, few studies have explored the comorbidity trajectories that patients with psoriasis commonly experience over time. This study reports the 5-year comorbidity trajectories of patients with psoriasis. OBJECTIVES: To determine the long-term comorbidity trajectories of patients with psoriasis in Denmark. METHODS: This observational cohort study explored the Danish National Patient Registry (DNPR) between 1999 and 2013 to identify comorbidities diagnosed 5 years prior to or after a psoriasis diagnosis. Comorbidity occurrence in patients with psoriasis (psoriasis cohort) was compared with patients without psoriasis (the N group). Comparison groups, each the same size as the psoriasis cohort, were created by selecting random patients from the N group. If a comorbidity occurrence was higher in more than nine comparison groups than in the psoriasis cohort, it was not analysed and only comorbidities that occurred in ≥ 0·8% of the psoriasis cohort were analysed. The strength of association between a psoriasis diagnosis and a comorbidity diagnosis was measured using relative risk (RR). All psoriasis and comorbidity pairs that achieved RR > 1 (P < 0·001) (known as a Diagnosed Pair) were tested for directionality to identify the sequence of diagnoses using a binomial test. Diagnosed Pairs with a statistically significant direction (Bonferroni corrected P-value < 0·025) were then used to create comorbidity trajectory clusters 5 years before and after a psoriasis diagnosis. RESULTS: A total of 17 683 patients with psoriasis were compared with 10 000 comparison groups. A total of 121 comorbidities met the minimum criteria that ≥ 0·8% of the psoriasis cohort were diagnosed with the comorbidity within 5 years (before or after) of their psoriasis diagnosis. Thirty-eight of these comorbidities achieved RR > 1 (P < 0·001) with psoriasis, of which 19 achieved a significant direction from psoriasis to a comorbidity (including psoriasis to hypothyroidism), and four achieved a significant direction from a comorbidity diagnosis to a psoriasis diagnosis (including Crohn disease to psoriasis); four of five comorbidity trajectories with three sequential diagnoses achieved an RR > 1 (P < 0·001) and a significant direction from psoriasis to the first comorbidity to the second comorbidity (including psoriasis to hypertension to atrial fibrillation and flutter). CONCLUSIONS: Comorbidity trajectories may support clinicians in conducting disease risk analyses of patients with psoriasis and help plan optimal treatment to prevent future high-risk comorbidities.
引用
- Rosenø NAL, Lørup EH, Richardson C, et al. Exploring disease comorbidities and temporal disease progression of psoriasis: an observational, retrospective, multi-database, cohort study. Br J Dermatol. 2023. PMID: 36637104. doi:10.1093/bjd/ljac086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。